Fomepizole Dosing During Continuous Renal Replacement Therapy (CRRT)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04649138

Enrollment

Registered

2020-12-02

Start date

2019-06-13

Completion date

2020-11-26

Last updated

2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Toxic Alcohol Poisoning

Brief summary

The project is a prospective observation study of patients with suspected or confirmed toxic alcohol poisoning treated with fomepizole and continuous renal replacement therapy (CRRT)

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients (over 18 year) with suspected or confirmed toxic alcohol poisoning treated with fomepizole and CRRT.

Exclusion criteria

* Patients who wish to withdraw from the study

Design outcomes

Primary

Measure	Time frame	Description
Measure minimum plasma concentration of fomepizole	through study completion, up to 72 hours	Plasma samples will be obtained up to every hour and before fomepizole is given

Secondary

Measure	Time frame	Description
Continuous renal replacement therapy (CRRT) clearance of fomepizole	through study completion, up to 72 hours	Plasma and dialysat samples will be obtained up to every hour
Determine saturation/sieving coefficient of fomepizole	through study completion, up to 72 hours	Plasma and dialysat samples will be obtained up to every hour

Countries

Norway

Outcome results